Go Pro
→ The only metrics you should watch as a day trader. (From The TradingPub) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 10.50 +0.50 (+5.00%)
As of 07/15/2026 11:28 AM Eastern
Compare

CRTX vs. KAV, BZT, FAR, RMR, and GSP

Should you buy CRISM Therapeutics stock or one of its competitors? MarketBeat compares CRISM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISM Therapeutics include Kavango Resources (KAV), Bezant Resources (BZT), Ferro-Alloy Resources (FAR), Rome Resources (RMR), and Gensource Potash (GSP). These companies are all part of the "other industrial metals & mining" industry.

How does CRISM Therapeutics compare to Kavango Resources?

CRISM Therapeutics (LON:CRTX) and Kavango Resources (LON:KAV) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

0.3% of CRISM Therapeutics shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by insiders. Comparatively, 8.7% of Kavango Resources shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Kavango Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Kavango Resources Neutral

CRISM Therapeutics has a net margin of 0.00% compared to Kavango Resources' net margin of -869.55%. Kavango Resources' return on equity of -68.85% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Kavango Resources -869.55%-68.85%-14.06%

Kavango Resources has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Kavango Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A
Kavango Resources£1.72M16.67-£5.48K-£0.48N/A

CRISM Therapeutics has a beta of 0.599, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Kavango Resources has a beta of 0.274, indicating that its stock price is 73% less volatile than the broader market.

Summary

Kavango Resources beats CRISM Therapeutics on 6 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to Bezant Resources?

Bezant Resources (LON:BZT) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Bezant Resources' return on equity of 21.18% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bezant ResourcesN/A 21.18% -41.17%
CRISM Therapeutics N/A -139.63%-26.77%

Bezant Resources has higher earnings, but lower revenue than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Bezant Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bezant ResourcesN/AN/A-£8.40K£0.0115.96
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A

Bezant Resources has a beta of 0.852, indicating that its share price is 15% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, indicating that its share price is 40% less volatile than the broader market.

1.5% of Bezant Resources shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 7.3% of Bezant Resources shares are owned by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Bezant Resources had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Bezant Resources and 0 mentions for CRISM Therapeutics. Bezant Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Bezant Resources Neutral
CRISM Therapeutics Neutral

Summary

Bezant Resources beats CRISM Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Ferro-Alloy Resources?

Ferro-Alloy Resources (LON:FAR) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Ferro-Alloy Resources presently has a consensus price target of GBX 30, indicating a potential upside of 576.74%. Given Ferro-Alloy Resources' stronger consensus rating and higher probable upside, equities research analysts plainly believe Ferro-Alloy Resources is more favorable than CRISM Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ferro-Alloy Resources
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
CRISM Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ferro-Alloy Resources has a beta of 0.841, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, suggesting that its stock price is 40% less volatile than the broader market.

In the previous week, Ferro-Alloy Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Ferro-Alloy Resources Neutral
CRISM Therapeutics Neutral

CRISM Therapeutics has lower revenue, but higher earnings than Ferro-Alloy Resources. Ferro-Alloy Resources is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ferro-Alloy Resources£4.53M5.75-£9.69M-£1.70N/A
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A

CRISM Therapeutics has a net margin of 0.00% compared to Ferro-Alloy Resources' net margin of -185.72%. Ferro-Alloy Resources' return on equity of 283.86% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ferro-Alloy Resources-185.72% 283.86% -21.47%
CRISM Therapeutics N/A -139.63%-26.77%

1.2% of Ferro-Alloy Resources shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 47.1% of Ferro-Alloy Resources shares are owned by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ferro-Alloy Resources beats CRISM Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CRISM Therapeutics compare to Rome Resources?

Rome Resources (LON:RMR) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Rome Resources' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Rome Resources Neutral
CRISM Therapeutics Neutral

Rome Resources has higher earnings, but lower revenue than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Rome Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rome ResourcesN/AN/AN/A-£2.04N/A
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A

Rome Resources' return on equity of -9.76% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rome ResourcesN/A -9.76% -3.97%
CRISM Therapeutics N/A -139.63%-26.77%

Rome Resources has a beta of 0.015397686, indicating that its stock price is 98% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.599, indicating that its stock price is 40% less volatile than the broader market.

4.1% of Rome Resources shares are held by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are held by institutional investors. 16.6% of Rome Resources shares are held by company insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Rome Resources beats CRISM Therapeutics on 5 of the 8 factors compared between the two stocks.

How does CRISM Therapeutics compare to Gensource Potash?

Gensource Potash (LON:GSP) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Gensource Potash's average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Gensource Potash Neutral
CRISM Therapeutics Neutral

Gensource Potash's return on equity of -45.96% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gensource PotashN/A -45.96% -10.31%
CRISM Therapeutics N/A -139.63%-26.77%

0.3% of CRISM Therapeutics shares are held by institutional investors. 6.2% of Gensource Potash shares are held by insiders. Comparatively, 50.5% of CRISM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CRISM Therapeutics has higher revenue and earnings than Gensource Potash. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Gensource Potash, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gensource PotashN/AN/A-£6.58M-£0.01N/A
CRISM Therapeutics£231K35.99-£792.20K-£5.10N/A

Gensource Potash has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, CRISM Therapeutics has a beta of 0.599, indicating that its stock price is 40% less volatile than the broader market.

Summary

CRISM Therapeutics beats Gensource Potash on 5 of the 9 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON Exchange
Market Cap£8.31M£1.47B£4.56B£2.77B
Dividend YieldN/A6.57%5.03%6.12%
P/E Ratio-2.0617.8620.93368.57
Price / Sales35.9953,599.096,443.1184,766.98
Price / CashN/A24.6326.5727.87
Price / Book0.245.498.777.90
Net Income-£792.20K£70.60M£157.11M£5.89B
7 Day Performance4.08%-1.43%-0.61%1.26%
1 Month Performance-4.55%-8.35%-5.71%-0.16%
1 Year Performance-9.40%66.53%38.93%62.97%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 10.50
+5.0%		N/A-2.8%£8.31M£231KN/A4
KAV
Kavango Resources
N/AGBX 0.65
-7.1%		N/A-40.5%£30.56M£1.72MN/A43
BZT
Bezant Resources
N/AGBX 0.15
+9.0%		N/A+211.1%£29.71MN/A16.295
FAR
Ferro-Alloy Resources
N/AGBX 4.49
-3.4%		GBX 30
+568.2%		-37.1%£27.33M£4.53MN/A1,000
RMR
Rome Resources
N/AGBX 0.33
+4.8%		N/A+14.8%£24.18MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The window is closing
We printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...
American Alternative | Sponsoredtc pixel
Under $1 while the market panics
President Trump just called on the Senate to pass the CLARITY Act “in honor” of the late Senator Lindsey Graha...
Crypto 101 Media | Sponsoredtc pixel
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
This Is How Financial Freedom Dies—And Most People Never See It Coming
While the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not b...
Priority Gold | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel